Join our daily newsletter At The Bell to receive exclusive market insights
- Imagion Biosystems (IBX) has received approval from the Human Research Ethics Committee (HREC) for its MagSense phase one breast cancer study
- MagSense is being trialled to effectively detect HER2 metastatic breast cancer in its early stages
- With the study now approved, Imagion can now proceed with the final contracts with individual study sites
- On the market today, Imagion is up 5 per cent and trading for 8.4 cents per share
Imagion Biosystems (IBX) has received the green light from the Human Research Ethics Committee (HREC) for its MagSense HER2 phase one study for breast cancer.
In August, the company submitted its MagSense phase one study for HREC approval.
MagSense is being trialled to effectively detect HER2 metastatic breast cancer in its early stages. In late June, the company planned the study and not long after raised $5 million towards this incentive.
With the study now approved, Imagion can proceed with the final contracts with individual study sites. The company plans on commencing the study in the December quarter of 2020.
The company says it is on track for manufacturing of the MagSense HER2 nanoparticle formulation and has successfully completed bulk batch production.
Imagion is expecting to complete the last stage in the Good Manufacturing Practice (GMP) on time to support the start of the study.
“We are very pleased with our progress and will now be working diligently with our planned study sites to commence the study this calendar quarter as we
have previously advised,” Executive Chairman Bob Proulx said.
On the market today, Imagion is up 5 per cent and trading for 8.4 cents per share at 12:50 pm AEDT.
